About: Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on September 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована у вересні 2009 (uk) مقالة علمية نشرت في سبتمبر 2009 (ar) scientific article published on September 2009 (en)
publication date	wds:Q37415341-4845A471-B78A-4FA9-AE6A-89405239CA85
publication date	2009-09-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37415341-88288F94-1A78-400A-AC65-F34374BA2794
language of work or name	English
cites work	wds:Q37415341-0AF393CE-F5FD-46BF-9308-1ED96C19879C wds:Q37415341-1BCC838D-457C-4004-986F-83FFD9415E89 wds:Q37415341-27AFC440-39A6-4C13-8E89-EB032965A369 wds:Q37415341-35E45A0F-8267-42B4-B582-311E7CF06455 wds:Q37415341-3DF89AF8-D4AC-491D-A4A0-69036791847B wds:Q37415341-58655D0B-7A08-4EC7-90FD-E08902352850 wds:Q37415341-6C6A256A-CD69-4308-A924-A7B6B8A3E30A wds:Q37415341-6CFCF17C-EA79-4B54-97EE-1E516957979F wds:Q37415341-82C25B98-A913-40CB-B25E-E9E230639ECD wds:Q37415341-8E337281-C3E5-46CC-899C-1EB2C9E38E36 wds:Q37415341-9A215C23-5AF8-4A28-85CD-5754CDD60D64 wds:Q37415341-9BF37101-0A9C-4D7C-805F-0FCF0416F8B1 wds:Q37415341-A21943C8-D1B8-45C2-B11C-1093DE9AE9A3 wds:Q37415341-D1166980-5325-469C-B598-869E9C5663B4 wds:Q37415341-D4AA8B4F-D879-43BE-89CE-3075C3FF409E wds:Q37415341-DECC6421-6D54-4613-8EC3-BA779150D78A wds:Q37415341-E75A4F71-A4EE-44CC-AC19-CF21CA979C47 wds:Q37415341-E9BF5E8C-CB07-4574-8E96-0F4DB7B6F1A1 wds:Q37415341-F23AF1E8-CEC8-4ACE-A396-E2B965CDF7ED wds:Q37415341-FB4FB868-B362-489D-B0A4-9D7DC81AC0FE
cites work	Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study Nonparametric Estimation from Incomplete Observations Sorafenib in advanced clear-cell renal-cell carcinoma Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer Sorafenib in advanced hepatocellular carcinoma Sorafenib Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma Advanced bladder and urothelial cancers A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma
author name string	wds:Q37415341-1253FB9A-D18B-41C0-9052-F8E9451CA1D7 wds:Q37415341-51F3A349-D8EB-48C2-BDA9-4D9A4635170E wds:Q37415341-6C146C68-439B-48FD-B4D5-485ACD84F1AC wds:Q37415341-9407CD56-0333-45C9-AE8D-BE9C655F7C0F wds:Q37415341-9B43845C-E364-4F4C-904D-030C1CFF6EA1 wds:Q37415341-B9F4084A-14FF-4768-B636-B64379283BF5
author name string	Robert Dreicer Bruce J Roth Hailun Li Mark Stein Robert DiPaola Michael Eleff
rdfs:label	Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (en) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (nl) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (ast)
skos:prefLabel	Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (en) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (nl) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (ast)
name	Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (en) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (nl) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (ast)
author	wds:Q37415341-E7D16D87-9865-474A-89F1-2EEE45FDC1D4
author	George Wilding
title	wds:Q37415341-9793E235-4233-4E33-8C97-4F63D9A8BA93
title	Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (en)
page(s)	wds:Q37415341-4C00B352-F2D6-485B-86CB-0B98CA5C4EE5
page(s)	4090-4095
instance of	wds:Q37415341-84BEE284-DED9-4113-9371-1D441CC0F98C
instance of	scholarly article
main subject	wds:Q37415341-26E4F715-67BE-474A-992F-E97113E7BA9A wds:Q37415341-570C9B01-625C-493F-A61F-232D5D828B6D
main subject	Patients phase II clinical trial
PubMed ID	wds:Q37415341-C48E85B9-9F61-458D-99FE-5C8D14BAFC89
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19536901
PubMed ID	19536901
published in	wds:Q37415341-421A8A0B-6AD1-4F90-9FE4-C5F9183DBF69
published in	Cancer
issue	wds:Q37415341-09D6B87F-2447-4E3D-81B4-0B4C990E5D9E

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software